Prior VTE, metastatic disease, and the use of chemotherapy or targeted therapy increase the risk.2,3 Additionally, biomarkers such as d-dimer, soluble p-selectin, and more are independent predictive risk factors for cancer-associated VTE.3 Finally, the 12-month cumulative incidence of VTE over the last 2 decades has increased 3-fold among patients with cancer and up to 6-fold in those receiving chemotherapy or targeted therapy.2 Therefore, VTE is an increasingly common problem in the cancer population. This evidence concerns the gene SELP and cancer.